Cobra Biologics, a contract development and manufacturing organization based in Keele, UK, has entered into a service agreement with Neuway Pharma, a Bonn, Germany-based biopharmaceutical company focused on developing drugs to treat severe orphan central nervous system (CNS) diseases, to develop a manufacturing process for the production of GMP-grade material of engineered protein capsules (EPCs) using SF9 cells and subsequent baculovirus infection.

The material will be used by Neuway to conduct GLP toxicity studies and initiate clinical development for treating progressive multifocal leukoencephalopathy, a neurodegenerative CNS disease. Neuway also uses its EPCs as a CNS drug-delivery platform by filling them with active drug substances.

Source: Cobra Biologics